13F-HR filed by Stonepine Capital Management, LLC
Stonepine Capital Management, LLC filed this 13F-HR for the quarter ended 2023-09-30, filed 2023-11-13, with 23 holding rows worth $301,032,343.
- Accession
- 0000935836-23-000688
- Filer
- CIK 1440771
- Filed
- 2023-11-13
- Accepted by EDGAR
- acceptance time not in the bulk data set
- Ingested
- Source
- SEC quarterly data set
13F report for Q3 2023
A holdings report, 23 entries on the cover page, a total value of $301,032,343 stated on the cover page (in dollars after the unit check, H1), rows summing to $301,032,343 with VALUE read as dollars as filed, 13F file number 028-17175. The quarter's positions are built on this report. The resolved quarter.
The information table after summing rows of one CUSIP and put or call (H4), with the CUSIP and issuer name as filed. Values in dollars after the unit check (method).
| Issuer as filed | CUSIP | Class | Amount | Value | Value read as | Type |
|---|---|---|---|---|---|---|
| QUIDELORTHO CORP COM | 219798105 | Stock | 658,794 | $48,118,314 | dollars as filed | |
| EVOLUS INC | 30052C107 | COM | 5,179,004 | $47,336,097 | dollars as filed | |
| AMYLYX PHARMACEUTICALS INC | 03237H101 | COM | 2,515,868 | $46,065,543 | dollars as filed | |
| ADMA BIOLOGICS INC | 000899104 | COM | 9,104,275 | $32,593,305 | dollars as filed | |
| LAKEFRONT BIOTHERAPEUTICS NV | 36315X101 | SPON ADR | 802,544 | $27,727,895 | dollars as filed | |
| ALIMERA SCIENCES INC | 016259202 | COM | 3,983,686 | $12,349,427 | dollars as filed | |
| MAXCYTE INC | 57777K106 | COM | 3,761,640 | $11,736,317 | dollars as filed | |
| XERIS BIOPHARMA HOLDINGS INC | 98422E103 | COM | 5,915,372 | $11,002,592 | dollars as filed | |
| GAMIDA CELL LTD | M47364100 | SHS | 7,965,865 | $8,204,841 | dollars as filed | |
| ATYR PHARMA INC | 002120202 | COM NEW | 4,626,624 | $7,310,066 | dollars as filed | |
| SCYNEXIS INC | 811292200 | COM NEW | 2,852,599 | $6,503,926 | dollars as filed | |
| XOMA ROYALTY CORPORATION | 98419J206 | COMMON STOCK | 436,602 | $6,151,722 | dollars as filed | |
| X4 Pharmaceuticals, Inc. | 98420X103 | COM | 5,273,685 | $5,748,317 | dollars as filed | |
| ATEA PHARMACEUTICALS INC | 04683R106 | COMMON STOCK | 1,720,000 | $5,160,000 | dollars as filed | |
| REZOLUTE INC | 76200L309 | COMMON STOCK | 3,072,476 | $4,055,668 | dollars as filed | |
| TELA BIO INC | 872381108 | COM | 491,919 | $3,935,352 | dollars as filed | |
| EXAGEN INC | 30068X103 | COM | 1,203,491 | $2,912,448 | dollars as filed | |
| IO BIOTECH INC | 449778109 | COM | 1,975,308 | $2,785,184 | dollars as filed | |
| GOSSAMER BIO INC COM | 38341P102 | Stock | 3,339,405 | $2,781,056 | dollars as filed | |
| DELCATH SYSTEMS INC | 24661P807 | COMMON STOCK | 686,240 | $2,779,272 | dollars as filed | |
| ASSERTIO HOLDINGS INC | 04546C205 | COM NEW | 951,197 | $2,435,064 | dollars as filed | |
| VANDA PHARMACEUTICALS INC | 921659108 | COM | 477,903 | $2,064,541 | dollars as filed | |
| AYTU BIOPHARMA INC | 054754858 | COM | 472,369 | $1,275,396 | dollars as filed |
Amendment chain
| Filing | Role | Filed | Accepted | Ingested |
|---|---|---|---|---|
| 13F-HR 0000935836-23-000688 | this filing | 2023-11-13 | acceptance time not in the bulk data set |